Immunovant Sciences Gmbh
Clinical trials sponsored by Immunovant Sciences Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame lupus skin flares Results expected Oct 2026 (estimated)
- New drug aims to tame overactive thyroid without lifelong pills Results expected May 2027 (estimated)
- New shot could help when arthritis drugs fail Results expected Sep 2027 (estimated)
-
New drug IMVT-1402 aims to stop CIDP relapses in Mid-Stage trial
Disease control Recruiting nowThis Phase 2b study tests whether the drug IMVT-1402 can help adults with CIDP, a nerve disorder causing weakness and numbness. About 162 participants will receive either the drug or a placebo weekly for up to 52 weeks. The main goal is to see if the drug keeps the disease from w…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without daily pills
Disease control Recruiting nowThis phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without lifelong pills
Disease control Recruiting nowThis trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug trial aims to ease muscle weakness in myasthenia gravis
Disease control Recruiting nowThis study tests an investigational drug called IMVT-1402 in 231 adults with mild to severe generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it improves daily activities and muscle strength. The goal i…
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC